{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:31Z","timestamp":1792787911250,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Gothenburg","id":[{"id":"https:\/\/ror.org\/01tm6cn81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Peptide receptor radionuclide therapy with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE is an established treatment for somatostatin receptor\u2013expressing neuroendocrine tumors. Although strong anti-tumor effects have been demonstrated in experimental models, curative responses in patients remain limited. Improved understanding of the molecular responses induced by [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE may help identify strategies for treatment optimization. This study aimed to characterize proteomic alterations in GOT1 small intestinal neuroendocrine tumor xenografts following [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      GOT1 tumor\u2013bearing BALB\/c nude mice received a non-curative intravenous administration of 15 MBq [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE or saline control. Tumors were collected 1 or 13 days after treatment to represent early response and regrowth phases. Tumor volumes were monitored using magnetic resonance imaging. Proteomic profiling was performed using liquid chromatography tandem mass spectrometry with tandem mass tag labeling. Differential protein expression was analyzed using Welch\u2019s t-test with significance defined as fold change\u2009\u2265\u20091.5 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01. Functional enrichment and pathway analyses were conducted using Gene Ontology annotation and Ingenuity Pathway Analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment induced a transient reduction in tumor volume followed by regrowth. In total, 3861 proteins were quantified, of which 155 showed significantly altered expression after treatment. Affected proteins were associated with cytoskeletal organization, oxidative stress response, protein metabolism, and systemic regulation. Pathway analyses identified inhibition of several signaling pathways linked to cell migration and invasiveness, including RhoA, Rac, integrin, and CXCR4 signaling. Upstream regulator analysis suggested activation of RABL6 and inhibition of p53 signaling during tumor regrowth. Proteins related to endoplasmic reticulum stress and ubiquitin-proteasome activity were also altered. Selected findings were validated by ELISA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE therapy induced extensive proteomic changes in GOT1 tumors, including suppression of pathways associated with invasiveness and modulation of p53- and stress-related signaling. These findings suggest potential therapeutic benefits of combining [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE with agents targeting p53 regulation or endoplasmic reticulum stress pathways to improve treatment efficacy in neuroendocrine tumors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16975-3","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:34:59Z","timestamp":1789522499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [177Lu]Lu-DOTATATE therapy"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-9786","authenticated-orcid":false,"given":"Johan K.E.","family":"Spetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9103-3446","authenticated-orcid":false,"given":"Mikael E.","family":"Montelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.M.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2982-3275","authenticated-orcid":false,"given":"Nishte","family":"Rassol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8991-2353","authenticated-orcid":false,"given":"Maria","family":"Ljungberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-4368","authenticated-orcid":false,"given":"Eva B.","family":"Forssell-Aronsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"4","key":"16975_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/09553008414552111","volume":"51","author":"R Teoule","year":"1987","unstructured":"Teoule R. Radiation-induced DNA damage and its repair. Int J radiation biology Relat Stud Phys Chem Med. 1987;51(4):573\u201389.","journal-title":"Int J radiation biology Relat Stud Phys Chem Med"},{"issue":"1","key":"16975_CR2","doi-asserted-by":"publisher","first-page":"e13409","DOI":"10.1111\/imr.13409","volume":"329","author":"S Saini","year":"2025","unstructured":"Saini S, Gurung P. A comprehensive review of sensors of radiation-induced damage, radiation-induced proximal events, and cell death. Immunol Rev. 2025;329(1):e13409.","journal-title":"Immunol Rev"},{"issue":"4","key":"16975_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11936-018-0627-x","volume":"20","author":"J Spetz","year":"2018","unstructured":"Spetz J, Moslehi J, Sarosiek K. Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment. Curr Treat Options Cardiovasc Med. 2018;20(4):31.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"20","key":"16975_CR4","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1158\/0008-5472.CAN-22-1337","volume":"83","author":"R Singh","year":"2023","unstructured":"Singh R, Yu S, Osman M, Inde Z, Fraser C, Cleveland AH, Almanzar N, Lim CB, Joshi GN, Spetz J, et al. Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX. Cancer Res. 2023;83(20):3442\u201361.","journal-title":"Cancer Res"},{"issue":"45","key":"16975_CR5","doi-asserted-by":"publisher","first-page":"eabn6579","DOI":"10.1126\/sciadv.abn6579","volume":"8","author":"JKE Spetz","year":"2022","unstructured":"Spetz JKE, Florido MHC, Fraser CS, Qin X, Choiniere J, Yu SJ, Singh R, Friesen M, Rubin LL, Salem JE, et al. Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy-induced toxicities. Sci Adv. 2022;8(45):eabn6579.","journal-title":"Sci Adv"},{"key":"16975_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fmed.2015.00012","volume":"2","author":"JP Pouget","year":"2015","unstructured":"Pouget JP, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy. Front Med. 2015;2:12.","journal-title":"Front Med"},{"key":"16975_CR7","doi-asserted-by":"crossref","unstructured":"Moncharmont C, Levy A, Guy JB, Falk AT, Guilbert M, Trone JC, Alphonse G, Gilormini M, Ardail D, Toillon RA, et al. Radiation-enhanced cell migration\/invasion process: a review. Critical reviews in oncology\/hematology. 2014, 92(2):133\u2013142.","DOI":"10.1016\/j.critrevonc.2014.05.006"},{"issue":"7","key":"16975_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.4161\/cc.6.7.4036","volume":"6","author":"L Moretti","year":"2007","unstructured":"Moretti L, Cha YI, Niermann KJ, Lu B. Switch between apoptosis and autophagy: radiation-induced endoplasmic reticulum stress? Cell Cycle. 2007;6(7):793\u20138.","journal-title":"Cell Cycle"},{"issue":"1","key":"16975_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2045-824X-5-19","volume":"5","author":"P Grabham","year":"2013","unstructured":"Grabham P, Sharma P. The effects of radiation on angiogenesis. Vascular cell. 2013;5(1):19.","journal-title":"Vascular cell"},{"issue":"4","key":"16975_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13277-010-0042-8","volume":"31","author":"D Eriksson","year":"2010","unstructured":"Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour biology: J Int Soc Oncodevelopmental Biology Med. 2010;31(4):363\u201372.","journal-title":"Tumour biology: J Int Soc Oncodevelopmental Biology Med"},{"key":"16975_CR11","doi-asserted-by":"crossref","unstructured":"Haikerwal SJ, Hagekyriakou J, MacManus M, Martin OA, Haynes NM. Building immunity to cancer with radiation therapy. Cancer Lett. 2015.","DOI":"10.1016\/j.canlet.2015.01.009"},{"key":"16975_CR12","doi-asserted-by":"crossref","unstructured":"Mageau E, Derbowka R, Dickinson N, Lefort N, Kovala AT, Boreham DR, Tai TC, Thome C, Tharmalingam S. Molecular mechanisms of radiation resistance in breast cancer: a systematic review of radiosensitization strategies. Curr Issues Mol Biol. 2025;47(8).","DOI":"10.3390\/cimb47080589"},{"key":"16975_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/bs.ircmb.2018.07.004","volume":"342","author":"J Spetz","year":"2019","unstructured":"Spetz J, Presser AG, Sarosiek KA. T Cells and Regulated Cell Death: Kill or Be Killed. Int Rev Cell Mol Biol. 2019;342:27\u201371.","journal-title":"Int Rev Cell Mol Biol"},{"issue":"18","key":"16975_CR14","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin oncology: official J Am Soc Clin Oncol. 2008;26(18):3063\u201372.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"4","key":"16975_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/MPA.0000000000000113","volume":"43","author":"ES Delpassand","year":"2014","unstructured":"Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O\u2019Dorisio TM, Kvols LK, Simon J, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014;43(4):518\u201325.","journal-title":"Pancreas"},{"issue":"6","key":"16975_CR16","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1007\/s00268-009-0387-6","volume":"34","author":"C Sward","year":"2010","unstructured":"Sward C, Bernhardt P, Ahlman H, Wangberg B, Forssell-Aronsson E, Larsson M, Svensson J, Rossi-Norrlund R, Kolby L. [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J Surg. 2010;34(6):1368\u201372.","journal-title":"World J Surg"},{"issue":"2","key":"16975_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"11","key":"16975_CR18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","volume":"13","author":"S Das","year":"2019","unstructured":"Das S, Al-Toubah T, El-Haddad G, Strosberg J. (177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019;13(11):1023\u201331.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"10","key":"16975_CR19","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.bjc.6602845","volume":"93","author":"L K\u00f6lby","year":"2005","unstructured":"K\u00f6lby L, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Forssell-Aronsson E, Macke H, Nilsson O. Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour. Br J Cancer. 2005;93(10):1144\u201351.","journal-title":"Br J Cancer"},{"issue":"5","key":"16975_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-L","volume":"92","author":"M de Jong","year":"2001","unstructured":"de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, et al. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J cancer J Int du cancer. 2001;92(5):628\u201333.","journal-title":"Int J cancer J Int du cancer"},{"issue":"1","key":"16975_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000336086","volume":"97","author":"E Forssell-Aronsson","year":"2013","unstructured":"Forssell-Aronsson E, Spetz J, Ahlman H. Radionuclide therapy via SSTR: future aspects from experimental animal studies. Neuroendocrinology. 2013;97(1):86\u201398.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"16975_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2174\/1871520611009030250","volume":"10","author":"O Nilsson","year":"2010","unstructured":"Nilsson O, Arvidsson Y, Johanson V, Forssell-Aronsson E, Ahlman H. New medical strategies for midgut carcinoids. Anti-cancer Agents Med Chem. 2010;10(3):250\u201369.","journal-title":"Anti-cancer Agents Med Chem"},{"key":"16975_CR23","doi-asserted-by":"crossref","unstructured":"Bakr H, Al-Awar A, Spetz JKE, Forssell-Aronsson E. Advances in somatostatin-receptor-targeting peptide receptor radionuclide therapy for neuroendocrine tumors: biological rationale, combination strategies, and clinical perspectives. In: Preprints. Preprints; 2026.","DOI":"10.20944\/preprints202608.0689.v1"},{"issue":"1","key":"16975_CR24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1186\/s12885-017-3524-x","volume":"17","author":"J Spetz","year":"2017","unstructured":"Spetz J, Langen B, Rudqvist N, Parris TZ, Helou K, Nilsson O, Forssell-Aronsson E. Hedgehog inhibitor sonidegib potentiates (177)Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice. BMC Cancer. 2017;17(1):528.","journal-title":"BMC Cancer"},{"issue":"11","key":"16975_CR25","doi-asserted-by":"publisher","first-page":"e0225260","DOI":"10.1371\/journal.pone.0225260","volume":"14","author":"V Sandblom","year":"2019","unstructured":"Sandblom V, Spetz J, Shubbar E, Montelius M, Stahl I, Swanpalmer J, Nilsson O, Forssell-Aronsson E. Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer. PLoS ONE. 2019;14(11):e0225260.","journal-title":"PLoS ONE"},{"key":"16975_CR26","first-page":"4","volume":"1","author":"A Romiani","year":"2024","unstructured":"Romiani A, Pettersson D, Rassol N, Simonsson K, Bakr H, Lind DE, Kov\u00e1cs A, Spetz J, Palmer RH, Hallberg B, et al. Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model. Ther vol. 2024;1:4\u201321.","journal-title":"Ther vol"},{"issue":"5","key":"16975_CR27","doi-asserted-by":"publisher","first-page":"e0233720","DOI":"10.1371\/journal.pone.0233720","volume":"15","author":"V Sandblom","year":"2020","unstructured":"Sandblom V, Spetz J, Shubbar E, Montelius M, Stahl I, Swanpalmer J, Nilsson O, Forssell-Aronsson E. Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors. PLoS ONE. 2020;15(5):e0233720.","journal-title":"PLoS ONE"},{"key":"16975_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nucmedbio.2018.01.006","volume":"60","author":"J Spetz","year":"2018","unstructured":"Spetz J, Rudqvist N, Langen B, Parris TZ, Dalmo J, Schuler E, Wangberg B, Nilsson O, Helou K, Forssell-Aronsson E. Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after (177)Lu[Lu]-octreotate therapy. Nucl Med Biol. 2018;60:11\u20138.","journal-title":"Nucl Med Biol"},{"issue":"10","key":"16975_CR29","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1080\/09553002.2025.2542318","volume":"101","author":"M Elvborn","year":"2025","unstructured":"Elvborn M, Rassol N, Pettersson D, Shubbar E, Spetz J, Helou K, Forssell-Aronsson E. Late apoptotic effects after treatment with 177Lu-octreotate in small-intestine neuroendocrine GOT1 tumor model. Int J Radiat Biol. 2025;101(10):1038\u201346.","journal-title":"Int J Radiat Biol"},{"issue":"4","key":"16975_CR30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1667\/RR13466.1","volume":"182","author":"S Paul","year":"2014","unstructured":"Paul S, Ghandhi SA, Weber W, Doyle-Eisele M, Melo D, Guilmette R, Amundson SA. Gene expression response of mice after a single dose of 137CS as an internal emitter. Radiat Res. 2014;182(4):380\u20139.","journal-title":"Radiat Res"},{"issue":"10","key":"16975_CR31","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.nucmedbio.2014.07.010","volume":"41","author":"E Sch\u00fcler","year":"2014","unstructured":"Sch\u00fcler E, Rudqvist N, Parris TZ, Langen B, Spetz J, Helou K, Forssell-Aronsson E. Time- and dose rate-related effects of internal 177Lu exposure on gene expression in mouse kidney tissue. Nucl Med Biol. 2014;41(10):825\u201332.","journal-title":"Nucl Med Biol"},{"key":"16975_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-014-0078-7","volume":"5","author":"B Langen","year":"2015","unstructured":"Langen B, Rudqvist N, Parris TZ, Sch\u00fcler E, Spetz J, Helou K, Forssell-Aronsson E. Transcriptional response in normal mouse tissues after i.v. 211At administration - response related to absorbed dose, dose rate, and time. EJNMMI Res. 2015;5:1.","journal-title":"EJNMMI Res"},{"issue":"1","key":"16975_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13550-015-0137-8","volume":"5","author":"N Rudqvist","year":"2015","unstructured":"Rudqvist N, Spetz J, Sch\u00fcler E, Langen B, Parris TZ, Helou K, Forssell-Aronsson E. Gene expression signature in mouse thyroid tissue after 131I and 211At exposure. EJNMMI Res. 2015;5(1):59.","journal-title":"EJNMMI Res"},{"issue":"4","key":"16975_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3109\/09553002.2016.1144944","volume":"92","author":"C Kumar","year":"2016","unstructured":"Kumar C, Shetake N, Desai S, Kumar A, Samuel G, Pandey BN. Relevance of radiobiological concepts in radionuclide therapy of cancer. Int J Radiat Biol. 2016;92(4):173\u201386.","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"16975_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13550-019-0500-2","volume":"9","author":"J Spetz","year":"2019","unstructured":"Spetz J, Langen B, Rudqvist NP, Parris TZ, Shubbar E, Dalmo J, Wangberg B, Nilsson O, Helou K, Forssell-Aronsson E. Transcriptional effects of (177)Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice. EJNMMI Res. 2019;9(1):28.","journal-title":"EJNMMI Res"},{"issue":"2","key":"16975_CR36","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0002-9440(10)64017-5","volume":"158","author":"L K\u00f6lby","year":"2001","unstructured":"K\u00f6lby L, Bernhardt P, Ahlman H, W\u00e4ngberg B, Johanson V, Wigander A, Forssell-Aronsson E, Karlsson S, Ahren B, Stenman G, et al. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol. 2001;158(2):745\u201355.","journal-title":"Am J Pathol"},{"key":"16975_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1196\/annals.1294.031","volume":"1014","author":"O Nilsson","year":"2004","unstructured":"Nilsson O, K\u00f6lby L, Bernhardt P, Forssell-Aronsson E, Johanson V, Ahlman H. GOT1 xenografted to nude mice: a unique model for in vivo studies on SSTR-mediated radiation therapy of carcinoid tumors. Ann N Y Acad Sci. 2004;1014:275\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"16975_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0002-9440(10)64017-5","volume":"158","author":"L Kolby","year":"2001","unstructured":"Kolby L, Bernhardt P, Ahlman H, Wangberg B, Johanson V, Wigander A, Forssell-Aronsson E, Karlsson S, Ahren B, Stenman G, et al. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol. 2001;158(2):745\u201355.","journal-title":"Am J Pathol"},{"issue":"3","key":"16975_CR39","doi-asserted-by":"publisher","first-page":"e4060","DOI":"10.1002\/nbm.4060","volume":"32","author":"M Montelius","year":"2019","unstructured":"Montelius M, Jalnefjord O, Spetz J, Nilsson O, Forssell-Aronsson E, Ljungberg M. Multiparametric MR for non-invasive evaluation of tumour tissue histological characteristics after radionuclide therapy. NMR Biomed. 2019;32(3):e4060.","journal-title":"NMR Biomed"},{"issue":"2","key":"16975_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.tranon.2017.12.003","volume":"11","author":"M Montelius","year":"2018","unstructured":"Montelius M, Spetz J, Jalnefjord O, Berger E, Nilsson O, Ljungberg M, Forssell-Aronsson E. Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor. Transl Oncol. 2018;11(2):193\u2013204.","journal-title":"Transl Oncol"},{"issue":"3","key":"16975_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet 21: a generalized schema for radiopharmaceutical dosimetry\u2013standardization of nomenclature. J nuclear medicine: official publication Soc Nuclear Med. 2009;50(3):477\u201384.","journal-title":"J nuclear medicine: official publication Soc Nuclear Med"},{"issue":"1","key":"16975_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13550-016-0247-y","volume":"7","author":"J Dalmo","year":"2017","unstructured":"Dalmo J, Spetz J, Montelius M, Langen B, Arvidsson Y, Johansson H, Parris TZ, Helou K, Wangberg B, Nilsson O, et al. Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1. EJNMMI Res. 2017;7(1):6.","journal-title":"EJNMMI Res"},{"issue":"3","key":"16975_CR43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.icrp.2008.10.001","volume":"38","author":"K Eckerman","year":"2008","unstructured":"Eckerman K, Endo A. ICRP Publication 107. Nuclear decay data for dosimetric calculations. Ann ICRP. 2008;38(3):7\u201396.","journal-title":"Ann ICRP"},{"key":"16975_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2342-12-12","volume":"12","author":"M Montelius","year":"2012","unstructured":"Montelius M, Ljungberg M, Horn M, Forssell-Aronsson E. Tumour size measurement in a mouse model using high resolution MRI. BMC Med Imaging. 2012;12:12.","journal-title":"BMC Med Imaging"},{"issue":"5","key":"16975_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth.1322","volume":"6","author":"JR Wisniewski","year":"2009","unstructured":"Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6(5):359\u201362.","journal-title":"Nat Methods"},{"issue":"1","key":"16975_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W Huang da","year":"2009","unstructured":"Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44\u201357.","journal-title":"Nat Protoc"},{"key":"16975_CR47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kramer","year":"2013","unstructured":"Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal Analysis Approaches in Ingenuity Pathway Analysis (IPA). Bioinformatics. 2013;30:523\u201330.","journal-title":"Bioinformatics"},{"issue":"4\u20136","key":"16975_CR48","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/ars.2021.0257","volume":"37","author":"JLO Pohjoismaki","year":"2022","unstructured":"Pohjoismaki JLO, Goffart S. Adaptive and Pathological Outcomes of Radiation Stress-Induced Redox Signaling. Antioxid Redox Signal. 2022;37(4\u20136):336\u201348.","journal-title":"Antioxid Redox Signal"},{"key":"16975_CR49","doi-asserted-by":"crossref","unstructured":"Ong G, Logue SE. Unfolding the interactions between endoplasmic reticulum stress and oxidative stress. Antioxid (Basel) 2023;12(5).","DOI":"10.3390\/antiox12050981"},{"issue":"1","key":"16975_CR50","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1038\/s41467-022-33461-z","volume":"13","author":"CS Fraser","year":"2022","unstructured":"Fraser CS, Spetz JKE, Qin X, Presser A, Choiniere J, Li C, Yu S, Blevins F, Hata AN, Miller JW, et al. Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics. Nat Commun. 2022;13(1):5789.","journal-title":"Nat Commun"},{"issue":"1","key":"16975_CR51","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41419-025-07978-2","volume":"16","author":"X Xie","year":"2025","unstructured":"Xie X, Tong W, Xie Y, Jiang H, Jiang A, Huang J, Liu Z, Yu J. Targeting the SYVN1-EGFR axis: a breakthrough strategy for TKI-resistant NSCLC. Cell Death Dis. 2025;16(1):655.","journal-title":"Cell Death Dis"},{"issue":"20","key":"16975_CR52","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1016\/j.febslet.2013.08.030","volume":"587","author":"T Yamamori","year":"2013","unstructured":"Yamamori T, Meike S, Nagane M, Yasui H, Inanami O. ER stress suppresses DNA double-strand break repair and sensitizes tumor cells to ionizing radiation by stimulating proteasomal degradation of Rad51. FEBS Lett. 2013;587(20):3348\u201353.","journal-title":"FEBS Lett"},{"issue":"2","key":"16975_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1247\/csf.09006","volume":"34","author":"K Tsutsumi","year":"2009","unstructured":"Tsutsumi K, Tsuda M, Yazawa N, Nakamura H, Ishihara S, Haga H, Yasuda M, Yamazaki R, Shirato H, Kawaguchi H, et al. Increased motility and invasiveness in tumor cells that survive 10 Gy irradiation. Cell Struct Funct. 2009;34(2):89\u201396.","journal-title":"Cell Struct Funct"},{"issue":"1","key":"16975_CR54","first-page":"1","volume":"13","author":"S Sai","year":"2023","unstructured":"Sai S, Koto M, Yamada S. Basic and translational research on carbon-ion radiobiology. Am J Cancer Res. 2023;13(1):1\u201324.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"16975_CR55","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2174\/1566524011313040008","volume":"13","author":"M Ruscica","year":"2013","unstructured":"Ruscica M, Arvigo M, Steffani L, Ferone D, Magni P. Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression. Curr Mol Med. 2013;13(4):555\u201371.","journal-title":"Curr Mol Med"},{"issue":"2","key":"16975_CR56","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1677\/ERC-09-0085","volume":"17","author":"Y Arvidsson","year":"2010","unstructured":"Arvidsson Y, Bergstr\u00f6m A, Arvidsson L, Kristiansson E, Ahlman H, Nilsson O. Hypoxia stimulates CXCR4 signalling in ileal carcinoids. Endocrine-related Cancer. 2010;17(2):303\u201316.","journal-title":"Endocrine-related Cancer"},{"issue":"3","key":"16975_CR57","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jbior.2013.07.006","volume":"53","author":"R Lattanzio","year":"2013","unstructured":"Lattanzio R, Piantelli M, Falasca M. Role of phospholipase C in cell invasion and metastasis. Adv Biol Regul. 2013;53(3):309\u201318.","journal-title":"Adv Biol Regul"},{"issue":"1","key":"16975_CR58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.surg.2015.10.016","volume":"159","author":"LA Shirley","year":"2016","unstructured":"Shirley LA, McCarty S, Yang MC, Saji M, Zhang X, Phay J, Ringel MD, Chen CS. Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target. Surgery. 2016;159(1):163\u201370.","journal-title":"Surgery"},{"issue":"8","key":"16975_CR59","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrm3153","volume":"12","author":"R Garcia-Mata","year":"2011","unstructured":"Garcia-Mata R, Boulter E, Burridge K. The \u2018invisible hand\u2019: regulation of RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol. 2011;12(8):493\u2013504.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"16975_CR60","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nrc3050","volume":"11","author":"SJ Storr","year":"2011","unstructured":"Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer. 2011;11(5):364\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"16975_CR61","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1134\/S0026893314020046","volume":"48","author":"AS Chikina","year":"2014","unstructured":"Chikina AS, Aleksandrova A. The cellular mechanisms and regulation of metastasis formation. Mol Biol. 2014;48(2):195\u2013213.","journal-title":"Mol Biol"},{"key":"16975_CR62","doi-asserted-by":"crossref","unstructured":"Smithers CC, Overduin m. structural mechanisms and drug discovery prospects of Rho GTPases. Cells. 2016;5(2).","DOI":"10.3390\/cells5020026"},{"issue":"3","key":"16975_CR63","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"16975_CR64","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1042\/BJ20141404","volume":"466","author":"R Goggs","year":"2015","unstructured":"Goggs R, Williams CM, Mellor H, Poole AW. Platelet Rho GTPases-a focus on novel players, roles and relationships. Biochem J. 2015;466(3):431\u201342.","journal-title":"Biochem J"},{"key":"16975_CR65","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1196\/annals.1410.034","volume":"1148","author":"D Jurkovicova","year":"2008","unstructured":"Jurkovicova D, Sedlakova B, Lacinova L, Kopacek J, Sulova Z, Sedlak J, Krizanova O. Hypoxia differently modulates gene expression of inositol 1,4,5-trisphosphate receptors in mouse kidney and HEK 293 cell line. Ann N Y Acad Sci. 2008;1148:421\u20137.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"16975_CR66","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/emboj\/17.5.1362","volume":"17","author":"T Azuma","year":"1998","unstructured":"Azuma T, Witke W, Stossel TP, Hartwig JH, Kwiatkowski DJ. Gelsolin is a downstream effector of rac for fibroblast motility. EMBO J. 1998;17(5):1362\u201370.","journal-title":"EMBO J"},{"issue":"36","key":"16975_CR67","doi-asserted-by":"publisher","first-page":"39127","DOI":"10.18632\/oncotarget.3926","volume":"6","author":"P Wong","year":"2015","unstructured":"Wong P, Hui A, Su J, Yue S, Haibe-Kains B, Gokgoz N, Xu W, Bruce J, Williams J, Catton C, et al. Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas. Oncotarget. 2015;6(36):39127\u201339.","journal-title":"Oncotarget"},{"issue":"1","key":"16975_CR68","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"RX Huang","year":"2020","unstructured":"Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5(1):60.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"16975_CR69","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","volume":"7","author":"JS Brown","year":"2017","unstructured":"Brown JS, O\u2019Carrigan B, Jackson SP, Yap TA. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov. 2017;7(1):20\u201337.","journal-title":"Cancer Discov"},{"issue":"7\u20138","key":"16975_CR70","doi-asserted-by":"publisher","first-page":"307","DOI":"10.18632\/genesandcancer.71","volume":"6","author":"K Lui","year":"2015","unstructured":"Lui K, Sheikh MS, Huang Y. Regulation of p53 oligomerization by Ras superfamily protein RBEL1A. Genes cancer. 2015;6(7\u20138):307\u201316.","journal-title":"Genes cancer"},{"issue":"5","key":"16975_CR71","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ctrv.2015.03.006","volume":"41","author":"F Briest","year":"2015","unstructured":"Briest F, Grabowski P. The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms. Cancer Treat Rev. 2015;41(5):423\u201330.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"16975_CR72","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1158\/1078-0432.CCR-12-3458","volume":"19","author":"K Oberg","year":"2013","unstructured":"Oberg K, Casanovas O, Castano JP, Chung D, Delle Fave G, Denefle P, Harris P, Khan MS, Kulke MH, Scarpa A, et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res. 2013;19(11):2842\u20139.","journal-title":"Clin Cancer Res"},{"issue":"7643","key":"16975_CR73","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature21063","volume":"543","author":"A Scarpa","year":"2017","unstructured":"Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65\u201371.","journal-title":"Nature"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16975-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:04:10Z","timestamp":1789635850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16975-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16975"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16975-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethical Committee for Animal Research at University of Gothenburg, Gothenburg, Sweden (Permit Number: 107\/15). All animal procedures were carried out in accordance with the ethical approval.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1111"}}